Edition:
United States

Rexahn Pharmaceuticals Inc (RNN.A)

RNN.A on American Stock Exchange

2.41USD
21 Sep 2017
Change (% chg)

$0.08 (+3.43%)
Prev Close
$2.33
Open
$2.35
Day's High
$2.42
Day's Low
$2.33
Volume
7,509
Avg. Vol
30,197
52-wk High
$7.10
52-wk Low
$1.29

Chart for

About

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein... (more)

Overall

Beta: -0.49
Market Cap(Mil.): $66.31
Shares Outstanding(Mil.): 28.46
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-Rexahn Pharmaceuticals receives new U.S. patent for Supinoxin

* Rexahn Pharmaceuticals receives new U.S. patent for Supinoxin Source text for Eikon: Further company coverage:

Aug 30 2017

BRIEF-Rexahn Pharmaceuticals reports Q2 earnings per share $0.04

* Rexahn Pharmaceuticals reports second quarter 2017 financial and operational results

Aug 07 2017

BRIEF-Rexahn pharmaceuticals receives notice of allowance for a new u.s. Patent covering the use of rx-3117

* Rexahn pharmaceuticals receives notice of allowance for a new u.s. Patent covering the use of rx-3117

Jul 10 2017

BRIEF-Rexahn Pharmaceuticals announces $10 mln registered direct offering

* Rexahn Pharmaceuticals Inc - net proceeds of offering will be used for further development of rexahn's lead clinical programs,

Jun 07 2017

BRIEF-Rexahn Pharmaceuticals files for mixed shelf offering of up to $150 mln‍​

* Rexahn Pharmaceuticals files for mixed shelf offering of up to $150 million - sec filing‍​ Source text (http://bit.ly/2s4PKc4) Further company coverage:

May 26 2017

BRIEF-Rexahn Pharmaceuticals reports Q1 loss per share $0.09

* Rexahn Pharmaceuticals reports first quarter 2017 financial results and provides corporate update

May 04 2017

BRIEF-Rexahn announces 1-for-10 reverse stock split

* Expects that reverse stock split will be effective on May 5, 2017 Source text for Eikon: Further company coverage:

Apr 13 2017

Competitors

  Price Chg
GlaxoSmithKline plc (GSK.L) 1,468.00 --
Merck & Co., Inc. (MRK.N) $65.60 -0.19

Earnings vs. Estimates